Vitiligo and Crohn′s disease form an autoimmune cluster: insights from a population-based study

References

• Picardo M, Dell’Anna ML, Ezzedine, K, et al. Vitiligo. Nat Rev Dis Primers. 2015;1(1):1–16.
   Google Scholar
• Ezzedine K, Eleftheriadou V, Whitton M, et al. Vitiligo. Lancet. 2015;386(9988):74–84.
   PubMed Web of Science ®Google Scholar
• Ongenae K, Geel NV, Naeyaert J-M. Evidence for an autoimmune pathogenesis of vitiligo. Pigment Cell Res. 2003;16(2):90–100.
   PubMedGoogle Scholar
• Ezzedine K, Lim HW, Suzuki T, on behalf of the Vitiligo Global Issue Consensus Conference panelists, et al. Revised classification/nomenclature of vitiligo and related issues: the vitiligo global issues consensus conference. Pigment Cell Melanoma Res. 2012;25(3):E1–E13.
   PubMed Web of Science ®Google Scholar
• Alkhateeb A, Fain PR, Thody A, et al. Epidemiology of vitiligo and associated autoimmune diseases in caucasian probands and their families. Pigment Cell Res. 2003;16(3):208–214.
   PubMedGoogle Scholar
• Spritz RA. Shared genetic relationships underlying generalized vitiligo and autoimmune thyroid disease. Thyroid. 2010;20(7):745–754.
   PubMedGoogle Scholar
• Kakourou T, Kanaka-Gantenbein C, Papadopoulou A, et al. Increased prevalence of chronic autoimmune (Hashimoto’s) thyroiditis in children and adolescents with vitiligo. J Am Acad Dermatol. 2005;53(2):220–223.
   PubMedGoogle Scholar
• Gey A, Diallo A, Seneschal J, et al. Autoimmune thyroid disease in vitiligo: multivariate analysis indicates intricate pathomechanisms. Br J Dermatol. 2013;168(4):756–761.
   PubMed Web of Science ®Google Scholar
• Zhang JZ, Abudoureyimu D, Wang M, et al. Association between celiac disease and vitiligo: a review of the literature. World J Clin Cases. 2021;9(34):10430–10437.
   PubMedGoogle Scholar
• Dahir AM, Thomsen SF. Comorbidities in vitiligo: comprehensive review. Int J Dermatol. 2018;57(10):1157–1164.
   PubMed Web of Science ®Google Scholar
• Baumgart DC, Sandborn WJ. Crohn’s disease. Lancet. 2012;380(9853):1590–1605.
   PubMed Web of Science ®Google Scholar
• Dessein R, Chamaillard M, Danese S. Innate immunity in Crohn’s disease: the reverse side of the medal. J Clin Gastroenterol. 2008;42(Supplement 3):S144–S147.
   PubMedGoogle Scholar
• Marks DJB, Rahman FZ, Sewell GW, et al. Crohn’s disease: an immune deficiency state. Clin Rev Allergy Immunol. 2010;38(1):20–31.
   PubMed Web of Science ®Google Scholar
• Ng SC, Shi HY, Hamidi N, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2017;390(10114):2769–2778.
   PubMed Web of Science ®Google Scholar
• Zhao M, Gönczi L, Lakatos PL, et al. The burden of inflammatory bowel disease in Europe in 2020. J Crohns Colitis. 2021;15(9):1573–1587.
   PubMed Web of Science ®Google Scholar
• Kaplan GG. The global burden of IBD: from 2015 to 2025. Nat Rev Gastroenterol Hepatol. 2015;12(12):720–727.
   PubMed Web of Science ®Google Scholar
• Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012;142(1):46–54.e42.
   PubMed Web of Science ®Google Scholar
• Annese V, Beaugerie L, Egan L, ECCO, et al. European evidence-based consensus: Inflammatory bowel disease and malignancies. J Crohns Colitis. 2015;9(11):945–965.
   PubMed Web of Science ®Google Scholar
• Beaugerie L, Itzkowitz SH. Cancers complicating inflammatory bowel disease. N Engl J Med. 2015;372(15):1441–1452.
   PubMed Web of Science ®Google Scholar
• Dignass A, Van Assche G, Lindsay JO, European Crohn’s and Colitis Organisation (ECCO), et al. The second european evidence-based consensus on the diagnosis and management of crohn’s disease: Current management. J Crohns Colitis. 2010;4(1):28–62.
   PubMed Web of Science ®Google Scholar
• Halling ML, Kjeldsen J, Knudsen T, et al. Patients with inflammatory bowel disease have increased risk of autoimmune and inflammatory diseases. WJG. 2017;23(33):6137–6146.
   PubMed Web of Science ®Google Scholar
• Pashankar D, Prendiville J, Israel DM. Vitiligo and Crohn’s disease in children. J Pediatr Gastroenterol Nutr. 1999;28(2):227–229.
   PubMedGoogle Scholar
• McPoland PR, Moss RL. Cutaneous crohn’s disease and progressive vitiligo. J Am Acad Dermatol. 1988;19(2):421–425.
   PubMedGoogle Scholar
• Greenland S, Thomas DC. On the need for the rare disease assumption in case-control studies. Am J Epidemiol. 1982;116(3):547–553.
   PubMed Web of Science ®Google Scholar
• Kridin K, Ludwig RJ, Schonmann Y, et al. The bidirectional association between bullous pemphigoid and psoriasis: a Population-Based cohort study. Front Med. 2020;7:511. DOI:10.3389/fmed.2020.00511
   PubMed Web of Science ®Google Scholar
• Cohen AD, Dreiher J, Regev-Rosenberg S, et al. The quality indigators program in clalit health services: the first decade. Harefuah. 2010;149(4):204–209, 265.
   PubMedGoogle Scholar
• McCann P, Pramanik A. Dysphagia and unexpected myasthenia gravis associated with primary biliary cirrhosis, ulcerative colitis and vitiligo. J Am Geriatr Soc. 2004;52(8):1407–1408. 8.
   PubMedGoogle Scholar
• Ryu TH, Lee DW, Choi JE, et al. A type II segmental vitiligo developed under infliximab treatment for ulcerative colitis. Ann Dermatol. 2017;29(6):826–827.
   PubMed Web of Science ®Google Scholar
• Aktas H, Ertuğrul G. Vitiligo in a COVID-19-vaccinated patient with ulcerative colitis: coincidence? Clin Experimental Derm. 2022;47(1):143–144.
   PubMedGoogle Scholar
• Jo UH, Lee JY, Lee H, et al. Various skin manifestations related to inflammatory bowel disease: a nationwide cross-sectional study on the korean population. J Dermatol. 2021;48(4):431–438.
   PubMedGoogle Scholar
• Kim M, Choi KH, Hwang SW, et al. Inflammatory bowel disease is associated with an increased risk of inflammatory skin diseases: a population-based cross-sectional study. J Am Acad Dermatol. 2017;76(1):40–48.
   PubMed Web of Science ®Google Scholar
• Bae JM, Kim M, Lee HH, et al. Increased risk of vitiligo following anti-Tumor necrosis factor therapy: a 10-Year Population-Based cohort study. J Invest Dermatol. 2018;138(4):768–774.
   PubMed Web of Science ®Google Scholar
• Somers EC, Thomas SL, Smeeth L, et al. Autoimmune diseases co-occurring within individuals and within families: a systematic review. Epidemiology. 2006;17(2):202–217.
   PubMedGoogle Scholar
• Szyper-Kravitz M, Marai I, Shoenfeld Y. Coexistence of thyroid autoimmunity with other autoimmune diseases: friend or foe? Additional aspects on the mosaic of autoimmunity. Autoimmunity. 2005;38(3):247–255.
   PubMed Web of Science ®Google Scholar
• Davidson A, Diamond B. Autoimmune diseases. N Engl J Med. 2001;345(5):340–350.
   PubMed Web of Science ®Google Scholar
• Speeckaert R, Lambert J, Bulat V, et al. Autoimmunity in segmental vitiligo. Front Immunol. 2020;11:568447–568448.
   PubMed Web of Science ®Google Scholar
• Stanescu AMA, Grajdeanu IV, Serban B, University of Medicine and Pharmacy “Carol Davila”, Bucharest, Romania, et al. Genetic implications in vitiligo and vitiligo-associated diseases. Arch Balk Med Union. 2019;54(1):161–165.
   Google Scholar
• Zheng J, Ibrahim S, Petersen F, et al. Meta-analysis reveals an association of PTPN22 C1858T with autoimmune diseases, which depends on the localization of the affected tissue. Genes Immun. 2012;13(8):641–652.
   PubMed Web of Science ®Google Scholar
• Shaw MH, Reimer T, Kim YG, et al. NOD-like receptors (NLRs): bona fide intracellular microbial sensors. Curr Opin Immunol. 2008;20(4):377–382.
   Google Scholar
• Somers EC, Thomas SL, Smeeth L, et al. Are individuals with an autoimmune disease at higher risk of a second autoimmune disorder? Am J Epidemiol. 2009;169(6):749–755.
   PubMedGoogle Scholar